Biological activities and quantitative structure-activity relationships of spiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-triones as aldose reductase inhibitors
摘要:
A series of spiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-triones were prepared and tested for aldose reductase inhibitory activity. The 6'-halogenated derivatives were found to be highly potent in vitro inhibitors of male rabbit lens aldose reductase and in vivo inhibitors of polyol accumulation in the sciatic nerves of galactosemic rats. Of these, (4R)-6'-chloro-3'-methylspiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-trione (67) showed the most potent in vitro and in vivo activities. An oral dose of 3 g/kg of compound 67 caused neither death nor behavioral abnormality in the preliminary acute toxicity study using mice and rats. Compound 67 was selected as a candidate for further evaluation. The quantitative structure-activity relationships in this series are also discussed.
Synthesis, characterization, antitumor, and cytotoxic activity of mononuclear Ru(II) complexes
摘要:
In the search for antitumor active metal complexes several ruthenium complexes have been reported to be promising. A series of mononuclear Ru(II) complexes, [Ru(T)2(S)]2+, where T = 2,2'-bipyridine/1,10-phenanthroline and S = CH3-bitsz, Cl-bitsz, Br-bitsz, tmtsz, dmtsz, have been prepared and characterized by UV-Vis, IR, 1H-NMR, FAB-mass spectroscopy, and elemental analysis. The complexes were subjected to invivo anticancer activity against a transplantable murine tumor cell line Ehrlich's ascitic carcinoma (EAC) and invitro cytotoxic activity against human cancer cell line Molt 4/C8, CEM, and murine tumor cell line L1210. Ruthenium complexes showed promising biological activity especially in decreasing tumor volume and viable ascitic cell counts. Treatment with these complexes prolonged the life span of EAC-tumor-bearing mice by 10-48%. Invitro evaluation of these ruthenium complexes revealed cytotoxic activity from 0.21 to 24 mu mol L-1 against Molt 4/C8, 0.16-19 mu mol L-1 against CEM, and 0.75-32 mu mol L-1 against L1210 cell proliferation, depending on the nature of the compound.
A cinchona alkaloid catalyzed enantioselective sulfa-Michael/aldol cascade reaction of isoindigos: construction of chiral bispirooxindole tetrahydrothiophenes with vicinal quaternary spirocenters
作者:Yong-Yuan Gui、Jian Yang、Liang-Wen Qi、Xiao Wang、Fang Tian、Xiao-Nian Li、Lin Peng、Li-Xin Wang
DOI:10.1039/c5ob00774g
日期:——
Enantioselective sulfa-Michael/aldol reaction of isoindigos has been successfully developed to afford bispirooxindole tetrahydrothiophenes with vicinal quaternary spirocenters.
Design and Synthesis of 3-Substituted Indolin-2-one Derivatives with Methyl (E)-2-(3-Methoxy)acrylate Moiety
作者:Xi Luo、Yi-Ying Zhang、Yu-Liang Wang
DOI:10.14233/ajchem.2015.18286
日期:——
In this article, fifteen indolin-2-one derivatives with methyl (E)-2-(3-methoxy)acrylate group were designed and synthesized. The structures of target compounds were confirmed by 1H NMR, IR and HR-MS spectra analysis.
LC-MS. The anticancer activity of the fourty-three new isatin derivatives against human T lymphocyte cells Jurkat was evaluated by MTT assay in vitro. SAR study suggested that the combination of 1-benzyl and 5-[trans-2-(methoxycarbonyl)ethen-1-yl] substitution greatly enhanced their cytotoxic activity. Among them, compound 2h was shown to have a significant cytotoxic activity with an IC50 value of
设计并合成了一系列新颖的二或三取代的靛红衍生物,以5–6的步骤合成,总产率为25–45%。它们的结构通过1 H NMR和13 C NMR以及LC-MS确认。体外MTT法检测了43种新的伊斯汀衍生物对人T淋巴细胞Jurkat的抗癌活性。SAR研究表明1-苄基和5- [反式-2-(甲氧羰基)乙烯-1-基]取代的组合大大增强了它们的细胞毒活性。其中,化合物2h被证明具有显着的细胞毒性活性,IC50值为0.03μM,比其母分子isatin高330倍以上。对细胞形态变化的研究和膜联蛋白-V / PI染色研究表明,化合物2h通过诱导凋亡来抑制Jurkat细胞的增殖。由于化合物2h诱导线粒体膜电位的耗散和caspase-3的激活,很明显,化合物2h通过线粒体的凋亡途径抑制Jurkat细胞的增殖。除此之外,化合物2h对许多其他肿瘤细胞具有抑制作用,并且仅显示出对人正常细胞的弱细胞毒性,这表明化合物2h 具有广泛的抗癌谱和对正常细胞的高安全性。
Design, synthesis and biological evaluation of dual acetylcholinesterase and phosphodiesterase 5A inhibitors in treatment for Alzheimer’s disease
treatment targeting acetylcholinesterase (AChE). Inhibition of phosphodiesterase 5A (PDE5A) has recently been validated as a potentially novel therapeutic approach for Alzheimer’s disease (AD). In this work, series of new compounds were designed, synthesized and evaluated as dual cholinesterase and PDE5A inhibitor. Biological results revealed that some of these compounds display good biological activities against
随着分子生物学和技术的最新研究进展,关于阿尔茨海默氏病(AD)进展的多种可信假说已被提出。多靶点药物已经成为AD的创新治疗方法。当前针对AD患者的临床治疗主要是针对乙酰胆碱酯酶(AChE)的姑息治疗。磷酸二酯酶5A(PDE5A)的抑制作用最近已被证实是阿尔茨海默氏病(AD)的一种潜在的新型治疗方法。在这项工作中,设计,合成和评估了一系列新化合物,作为双胆碱酯酶和PDE5A抑制剂。生物学结果表明,其中一些化合物对AChE表现出良好的生物学活性,IC 50值约为44.67–169.80 nM(多奈哌齐IC 5050.12 nM)。值得注意的是,化合物12表现出对PDE5A的有效活性,IC 50值约为50μM(sildenafil IC 50为12.59μM),其中一些化合物在体外对A549细胞的毒性较低。
Methylisoindigo and Its Bromo-Derivatives Are Selective Tyrosine Kinase Inhibitors, Repressing Cellular Stat3 Activity, and Target CD133+ Cancer Stem Cells in PDAC
selectively inhibited Stat3-associated tyrosine kinases and further confirmed its activity in cell based assays. To gain a deeper insight into the structure–activity relationship we produced 7 bromo-derivatives exhausting the accessible positions on the bisindole backbone except for in the 4-position due to the space limitation. We compared their anti-proliferative effects on tumor cells. We found that